EP4486345A1 — Method of treatment including kras g12c inhibitors and shp2 inhibitors
Assigned to Eli Lilly and Co · Expires 2025-01-08 · 1y expired
What this patent protects
The present disclosure provides method of treating a patient for cancer, comprising administering to a patient in need thereof, effective amounts of a compound of the formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A, B, and Y are as described herein, or pharmac…
USPTO Abstract
The present disclosure provides method of treating a patient for cancer, comprising administering to a patient in need thereof, effective amounts of a compound of the formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A, B, and Y are as described herein, or pharmaceutically acceptable salts thereof, and a SHP2 inhibitor, or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Lumakras (SOTORASIB) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.